Cargando…

Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study

Dalbavancin is a semisynthetic lipoglycopeptide, which possesses great potential for bactericidal activity similar to antimicrobials with the same mechanism of action, such as vancomycin and teicoplanin. Due to its very prolonged half-life, it can be used in a single or two-dose regimen to treat inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Petros, Wolff, Nora, Mathioudaki, Anna, Spanias, Christos, Spernovasilis, Nikolaos, Kofteridis, Diamantis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376731/
https://www.ncbi.nlm.nih.gov/pubmed/37508301
http://dx.doi.org/10.3390/antibiotics12071205
_version_ 1785079344632168448
author Ioannou, Petros
Wolff, Nora
Mathioudaki, Anna
Spanias, Christos
Spernovasilis, Nikolaos
Kofteridis, Diamantis P.
author_facet Ioannou, Petros
Wolff, Nora
Mathioudaki, Anna
Spanias, Christos
Spernovasilis, Nikolaos
Kofteridis, Diamantis P.
author_sort Ioannou, Petros
collection PubMed
description Dalbavancin is a semisynthetic lipoglycopeptide, which possesses great potential for bactericidal activity similar to antimicrobials with the same mechanism of action, such as vancomycin and teicoplanin. Due to its very prolonged half-life, it can be used in a single or two-dose regimen to treat infections by Gram-positive microorganisms, even resistant ones, such as methicillin-resistant Staphylococcus aureus (MRSA). Currently, it is approved only for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). The aim of this study was to investigate the clinical and microbiological characteristics of patients to whom dalbavancin was administered at the University Hospital of Heraklion and evaluate its use in regard to the COVID-19 pandemic. In total, 146 patients were included in this retrospective cohort study evaluating the use of dalbavancin from the first time it was used in 2017 until the end of 2022. The median age was 68 years (range: 21–96 years), and 86 (59%) patients were male. The most common indications for dalbavancin use were osteoarticular infections in 43%, followed by ABSSSIs in 37%, and cardiovascular infections in 10%. Dalbavancin was used empirically in one out of three patients, most commonly with the indication of ABSSSIs, and most commonly in the post-COVID-19 era. The most frequently isolated pathogens were coagulase-negative staphylococci in 70%, S. aureus in 27%, Enterococcus spp. in 22%, and Streptococcus spp. in 8%, while one out of three infections were polymicrobial. In 12% of patients, the infection was not cured, but no patients died. For patients with ABSSSIs, endocarditis and vascular infections, and bacteremia, the cure rates were more than 90%, and in osteoarticular infections, the cure rate was 76%. Thus, dalbavancin has great potential for use in complicated and invasive infections that may require prolonged intravenous antimicrobial treatment. However, further studies are required to formally investigate its role in such infections.
format Online
Article
Text
id pubmed-10376731
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103767312023-07-29 Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study Ioannou, Petros Wolff, Nora Mathioudaki, Anna Spanias, Christos Spernovasilis, Nikolaos Kofteridis, Diamantis P. Antibiotics (Basel) Article Dalbavancin is a semisynthetic lipoglycopeptide, which possesses great potential for bactericidal activity similar to antimicrobials with the same mechanism of action, such as vancomycin and teicoplanin. Due to its very prolonged half-life, it can be used in a single or two-dose regimen to treat infections by Gram-positive microorganisms, even resistant ones, such as methicillin-resistant Staphylococcus aureus (MRSA). Currently, it is approved only for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). The aim of this study was to investigate the clinical and microbiological characteristics of patients to whom dalbavancin was administered at the University Hospital of Heraklion and evaluate its use in regard to the COVID-19 pandemic. In total, 146 patients were included in this retrospective cohort study evaluating the use of dalbavancin from the first time it was used in 2017 until the end of 2022. The median age was 68 years (range: 21–96 years), and 86 (59%) patients were male. The most common indications for dalbavancin use were osteoarticular infections in 43%, followed by ABSSSIs in 37%, and cardiovascular infections in 10%. Dalbavancin was used empirically in one out of three patients, most commonly with the indication of ABSSSIs, and most commonly in the post-COVID-19 era. The most frequently isolated pathogens were coagulase-negative staphylococci in 70%, S. aureus in 27%, Enterococcus spp. in 22%, and Streptococcus spp. in 8%, while one out of three infections were polymicrobial. In 12% of patients, the infection was not cured, but no patients died. For patients with ABSSSIs, endocarditis and vascular infections, and bacteremia, the cure rates were more than 90%, and in osteoarticular infections, the cure rate was 76%. Thus, dalbavancin has great potential for use in complicated and invasive infections that may require prolonged intravenous antimicrobial treatment. However, further studies are required to formally investigate its role in such infections. MDPI 2023-07-19 /pmc/articles/PMC10376731/ /pubmed/37508301 http://dx.doi.org/10.3390/antibiotics12071205 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ioannou, Petros
Wolff, Nora
Mathioudaki, Anna
Spanias, Christos
Spernovasilis, Nikolaos
Kofteridis, Diamantis P.
Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
title Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
title_full Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
title_fullStr Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
title_full_unstemmed Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
title_short Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic—A Single-Center Retrospective Study
title_sort real-world data regarding dalbavancin use before and during the covid-19 pandemic—a single-center retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376731/
https://www.ncbi.nlm.nih.gov/pubmed/37508301
http://dx.doi.org/10.3390/antibiotics12071205
work_keys_str_mv AT ioannoupetros realworlddataregardingdalbavancinusebeforeandduringthecovid19pandemicasinglecenterretrospectivestudy
AT wolffnora realworlddataregardingdalbavancinusebeforeandduringthecovid19pandemicasinglecenterretrospectivestudy
AT mathioudakianna realworlddataregardingdalbavancinusebeforeandduringthecovid19pandemicasinglecenterretrospectivestudy
AT spaniaschristos realworlddataregardingdalbavancinusebeforeandduringthecovid19pandemicasinglecenterretrospectivestudy
AT spernovasilisnikolaos realworlddataregardingdalbavancinusebeforeandduringthecovid19pandemicasinglecenterretrospectivestudy
AT kofteridisdiamantisp realworlddataregardingdalbavancinusebeforeandduringthecovid19pandemicasinglecenterretrospectivestudy